Completed PHASE4 INTERVENTIONAL 2-arm NCT03089333

Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects

Effects of Dapagliflozin, an SGLT2 Inhibitor, on Hemodynamic Parameters, Target Organ Damage and Obesity Profile in Resistant Hypertensive Subjects

Sponsor: Fundação de Amparo à Pesquisa do Estado de São Paulo

Conditions Blood Pressure Cardiac Hypertrophy Diabetes Mellitus, Type 2 Hypertension Microalbuminuria Obesity Vascular Stiffness

Interventions Dapagliflozin 10mg Glibenclamide 5Mg Tablet

Updated 6 times since 2017 Last updated: May 2, 2018 Started: Jul 31, 2016 Primary completion: Oct 31, 2017 Completion: Dec 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03089333, this PHASE4 trial focuses on Blood Pressure and Cardiac Hypertrophy and remains completed. Sponsored by Fundação de Amparo à Pesquisa do Estado de São Paulo, it has been updated 6 times since 2016, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

Status: Recruiting → Completed
May 2017 — Jun 2018 [monthly]

Recruiting PHASE4

Phase: PHASE2 → PHASE4

▶ Show 1 earlier version

Apr 2017 — May 2017 [monthly]

Recruiting PHASE2

First recorded

Jul 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fundação de Amparo à Pesquisa do Estado de São Paulo
University of Campinas, Brazil

Data source: University of Campinas, Brazil

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Campinas, Brazil